HLN

UBS says an early rise in flu cases could boost 2027 earnings for Reckitt and Haleon. The bank rates Reckitt a buy with a 7,600p target.

Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing Haleon Canada invites Torontonians to experience the Haleon Health House Haleon Canada invites Torontonians to experience the Haleon Health House TORONTO, Oct.

Haleon launched Excedrin Rapid Relief, an aspirin‑free, caffeine‑free pain reliever with fast‑release tech. The product is promoted through a nostalgic digital pet campaign that highlights quick headache relief.

The article lists three UK AI‑driven healthcare stocks, noting that software can scale without heavy hardware needs. It suggests these stocks may offer better value than hardware‑focused AI projects.

Haleon used a nostalgic digital pet game to promote Excedrin Rapid Relief, aiming to reshape its consumer health brand moat. The campaign uses interactive nostalgia to illustrate fast headache relief.

Haleon has delivered a 10.9% total return over three years, raising questions about whether its current price reflects its cash generation.

Haleon’s Excedrin push, featuring a virtual pet campaign, has helped the stock recover some of its year‑to‑date decline. The move may present a valuation opportunity as the company rebuilds momentum.